Abstract
A study group gathered by the Pharmacy & Therapeutics Society reviewed data on the Department of Veterans Affairs (VA) health care system's implementation of a new technology (insulin glargine) for patients with diabetes. It examined local implementation of VA criteria for nonformulary use of insulin glargine in 21 VA treatment facilities that were surveyed about the issue. The examination found differences in the use of insulin glargine across the 21 treatment facilities and in the approach to implementing the criteria for nonformulary use of insulin glargine used at the individual VA treatment facility level. Differences were identified regarding the respective roles of endocrinologists and PCPs in prescribing insulins, including insulin glargine. The study group urges further short- and long-term research to better understand the utilization, cost, and health outcome implications of the implementation process for the nonformulary criteria. Lessons learned from such research could benefit other health care systems and formulary committees.
| Original language | English (US) |
|---|---|
| Journal | Managed Care Interface |
| Volume | 20 |
| Issue number | 3 |
| State | Published - Mar 2007 |
Fingerprint
ASJC Scopus subject areas
- Health Policy
Cite this
Adoption of a new technology in a veterans affairs national formulary system with local implementation : The insulin glargine example. / Barengolts, Elena I.; Burke, Brian V.; Duckworth, William C.; Kaminsky, Robert; Miller, Donald R.; Swislocki, Arthur L.
In: Managed Care Interface, Vol. 20, No. 3, 03.2007.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Adoption of a new technology in a veterans affairs national formulary system with local implementation
T2 - The insulin glargine example
AU - Barengolts, Elena I.
AU - Burke, Brian V.
AU - Duckworth, William C.
AU - Kaminsky, Robert
AU - Miller, Donald R.
AU - Swislocki, Arthur L
PY - 2007/3
Y1 - 2007/3
N2 - A study group gathered by the Pharmacy & Therapeutics Society reviewed data on the Department of Veterans Affairs (VA) health care system's implementation of a new technology (insulin glargine) for patients with diabetes. It examined local implementation of VA criteria for nonformulary use of insulin glargine in 21 VA treatment facilities that were surveyed about the issue. The examination found differences in the use of insulin glargine across the 21 treatment facilities and in the approach to implementing the criteria for nonformulary use of insulin glargine used at the individual VA treatment facility level. Differences were identified regarding the respective roles of endocrinologists and PCPs in prescribing insulins, including insulin glargine. The study group urges further short- and long-term research to better understand the utilization, cost, and health outcome implications of the implementation process for the nonformulary criteria. Lessons learned from such research could benefit other health care systems and formulary committees.
AB - A study group gathered by the Pharmacy & Therapeutics Society reviewed data on the Department of Veterans Affairs (VA) health care system's implementation of a new technology (insulin glargine) for patients with diabetes. It examined local implementation of VA criteria for nonformulary use of insulin glargine in 21 VA treatment facilities that were surveyed about the issue. The examination found differences in the use of insulin glargine across the 21 treatment facilities and in the approach to implementing the criteria for nonformulary use of insulin glargine used at the individual VA treatment facility level. Differences were identified regarding the respective roles of endocrinologists and PCPs in prescribing insulins, including insulin glargine. The study group urges further short- and long-term research to better understand the utilization, cost, and health outcome implications of the implementation process for the nonformulary criteria. Lessons learned from such research could benefit other health care systems and formulary committees.
UR - http://www.scopus.com/inward/record.url?scp=33947572522&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33947572522&partnerID=8YFLogxK
M3 - Article
C2 - 17458480
AN - SCOPUS:33947572522
VL - 20
JO - Managed Care Interface
JF - Managed Care Interface
SN - 1096-5645
IS - 3
ER -